<DOC>
	<DOCNO>NCT00004125</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know regimen chemotherapy effective breast cancer . PURPOSE : Randomized phase III trial compare effectiveness two different regimen combination chemotherapy treat woman stage II stage IIIA breast cancer spread lymph node .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Women With Stage II Stage IIIA Breast Cancer That Has Spread Lymph Nodes</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival overall survival patient node-positive high-risk node-negative operable stage II IIIA breast cancer treat docetaxel paclitaxel doxorubicin cyclophosphamide . - Determine whether weekly administration paclitaxel docetaxel 12 week improve disease-free survival overall survival compare conventional schedule every 3 week 4 course doxorubicin cyclophosphamide patient population . - Compare toxic effect docetaxel paclitaxel administer weekly 12 week versus every 3 week 4 course patient . - Compare toxicity paclitaxel administer every 3 week 4 course weekly 12 week docetaxel administer schedule patient . OUTLINE : This randomize , multicenter study . Patients stratify accord estrogen receptor status ( positive v negative v unknown ) , nodal status ( 0 positive node v 1-3 positive node v 4-9 positive node vs least 10 positive node ) , tumor size ( 5 cm v 5 cm v unknown ) , type prior surgery ( mastectomy v breast conservation surgery ) . Patients randomize one four treatment arm . - Arm I : Patients receive doxorubicin IV cyclophosphamide IV every 3 week 4 course ( week 1-12 ) . Beginning week 13 , patient receive paclitaxel IV 3 hour every 3 week 4 course . - Arm II : Patients receive doxorubicin cyclophosphamide arm I . Beginning week 13 , patient receive paclitaxel IV 1 hour weekly 12 week . - Arm III : Patients receive doxorubicin cyclophosphamide arm I . Beginning week 13 , patient receive docetaxel IV 1 hour every 3 week 4 course . - Arm IV : Patients receive doxorubicin cyclophosphamide arm I . Beginning week 13 , patient receive docetaxel IV 1 hour weekly 12 week . Within 4 week completion chemotherapy , patient estrogen and/or progesterone receptor positive tumor receive oral tamoxifen daily 5 year . After completion chemotherapy , patient prior segmental mastectomy receive radiotherapy daily 5 day per week 5-6 week . Patients prior modify radical mastectomy may receive radiotherapy chemotherapy completion investigator 's discretion . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 5,000 patient accrue study within 1.27 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm operable stage IIA , IIB , IIIA adenocarcinoma breast histologically involved lymph node ( T1 , 2 , 3 ; N1 2 ; M0 ) OR highrisk nodenegative disease ( T2 3 ; N0 ) Primary tumor least 2.1 cm diameter nodenegative disease Bilateral breast disease allow least 1 primary tumor meet criteria Must least 6 axillary lymph node remove dissection least one node positive metastasis OR Sentinel node biopsy negative metastasis ( sentinel node biopsy positive allow enrolled American College Surgery Trial Z0011 beenrandomized receive axillary dissection ) Additional axillary node may obtain provide also negative metastasis Complete tumor removal either modified radical mastectomy local excision plus axillary lymph node dissection ( i.e. , breast conservation therapy ) sentinel node biopsy Tumorfree margin least 1 mm invasive noninvasive carcinoma except lobular carcinoma situ ( le 1 mm allow ) Concurrent enrollment American College Surgery Trial Z0010 , Z0011 , NSABP B32 allow Hormone receptor status : Estrogen receptor status positive , negative , unknown PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No history myocardial infarction No congestive heart failure No significant ischemic valvular heart disease Other : No prior invasive malignancy within past 5 year except curatively treat basal squamous cell skin cancer carcinoma situ cervix No hypersensitivity paclitaxel docetaxel similarly formulate drug ( Cremophor polysorbate ) Not pregnant nursing Fertile patient must use effective barrier contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy breast cancer Endocrine therapy : Prior tamoxifen 4 week duration breast cancer allow Prior tamoxifen selective estrogen receptor modulator ( SERM ) chemoprevention ( e.g. , Breast Cancer Prevention Trial ) indication ( e.g. , osteoporosis ) allow No concurrent tamoxifen SERMs Radiotherapy : No prior radiotherapy malignancy At least 2 week since prior radiotherapy breast ductal carcinoma situ Surgery : See Disease Characteristics Less 84 day since prior surgical procedure adequately treat primary tumor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>